JP2023516381A5 - - Google Patents
Info
- Publication number
- JP2023516381A5 JP2023516381A5 JP2022552782A JP2022552782A JP2023516381A5 JP 2023516381 A5 JP2023516381 A5 JP 2023516381A5 JP 2022552782 A JP2022552782 A JP 2022552782A JP 2022552782 A JP2022552782 A JP 2022552782A JP 2023516381 A5 JP2023516381 A5 JP 2023516381A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- amino acid
- alkyl
- formula
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2020-0026381 | 2020-03-03 | ||
| KR20200026381 | 2020-03-03 | ||
| PCT/KR2021/002622 WO2021177721A1 (ko) | 2020-03-03 | 2021-03-03 | Kras 돌연변이 및 활성화된 ron이 존재하는 암의 예방 또는 치료용 약학 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023516381A JP2023516381A (ja) | 2023-04-19 |
| JP2023516381A5 true JP2023516381A5 (enExample) | 2024-03-12 |
Family
ID=77612768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022552782A Pending JP2023516381A (ja) | 2020-03-03 | 2021-03-03 | Ｋｒａｓ変異および活性化ｒｏｎが存在する癌の予防または治療のための医薬組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230099204A1 (enExample) |
| EP (1) | EP4115887A4 (enExample) |
| JP (1) | JP2023516381A (enExample) |
| KR (1) | KR20210111711A (enExample) |
| CN (1) | CN115209900A (enExample) |
| WO (1) | WO2021177721A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| US20220235064A1 (en) * | 2019-08-02 | 2022-07-28 | Wellmarker Bio Co., Ltd. | Oxo-pyridine fusion ring derivative and pharmaceutical composition comprising same |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| KR20230144483A (ko) * | 2022-04-06 | 2023-10-16 | 웰마커바이오 주식회사 | Ron 돌연변이와 관련된 두경부암 예방 또는 치료용 약학 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2089364T1 (sl) | 2006-11-08 | 2013-10-30 | Bristol-Myers Squibb Company | Spojine piridinona |
| CN102816175B (zh) * | 2011-06-09 | 2015-12-16 | 上海汇伦生命科技有限公司 | 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途 |
| RU2014102935A (ru) | 2011-08-02 | 2015-09-10 | Пфайзер Инк. | Кризотиниб для применения в лечении рака |
| EP2836482B1 (en) * | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| KR101350006B1 (ko) * | 2012-09-06 | 2014-02-13 | 씨제이제일제당 (주) | 피리돈 유도체를 포함하는 단백질 키나제 억제제 |
| US11564915B2 (en) | 2013-04-04 | 2023-01-31 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| CN107517590B (zh) * | 2014-07-29 | 2021-11-12 | 威马克生物有限公司 | 与表皮生长因子受体-靶制剂有关的感受性预测用新型生物标志物及其用途 |
| US11946934B2 (en) * | 2014-09-03 | 2024-04-02 | Wellmarker Bio Co., Ltd. | Biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof |
| WO2019182274A1 (en) * | 2018-03-08 | 2019-09-26 | Wellmarker Bio Co., Ltd. | Thienopyridine derivatives and pharmaceutical composition comprising same |
| US20220235064A1 (en) * | 2019-08-02 | 2022-07-28 | Wellmarker Bio Co., Ltd. | Oxo-pyridine fusion ring derivative and pharmaceutical composition comprising same |
| EP3819300A4 (en) * | 2019-09-06 | 2021-11-24 | Wellmarker Bio Co., Ltd. | THERAPEUTIC COMPOSITION BASED ON BIOMARKERS |
| JP2023513675A (ja) * | 2020-02-06 | 2023-04-03 | ウェルマーカー・バイオ・カンパニー・リミテッド | Ｋｒａｓ変異に関連する癌の予防または治療のための医薬組成物 |
-
2021
- 2021-03-03 KR KR1020210028396A patent/KR20210111711A/ko active Pending
- 2021-03-03 US US17/800,141 patent/US20230099204A1/en not_active Abandoned
- 2021-03-03 JP JP2022552782A patent/JP2023516381A/ja active Pending
- 2021-03-03 CN CN202180017888.8A patent/CN115209900A/zh active Pending
- 2021-03-03 WO PCT/KR2021/002622 patent/WO2021177721A1/ko not_active Ceased
- 2021-03-03 EP EP21764686.8A patent/EP4115887A4/en not_active Withdrawn